Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sufentanil sublingual tablet in post-operative pain
NCT02662556Phase 3Completed
- Sponsor
- Talphera
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of SurBred in postoperative pain, sponsored by Talphera. Primary endpoint: Time-weighted Summed Pain Intensity Difference Over the 12-hour Study Period. Started Mar 2016; status: completed.
02
Drugs
SurBred
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02662556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662556.